Politics
about 4 hours ago
Trump Accelerates Psychedelic Drug Review
President Donald Trump issued an executive order on April 18, 2026, to fast-track the review and research of psychedelic drugs like ibogaine for serious mental illnesses such as PTSD and severe depression. This landmark directive aims to ease restrictions, prioritize FDA approval, allocate $50 million for ibogaine research, and establish patient access pathways, potentially marking a significant shift in federal drug policy.
President Donald Trump issued an executive order on April 18, 2026, to fast-track the review and research of psychedelic drugs like ibogaine for serious mental illnesses such as PTSD and severe depression.
Catamist Editorial